PAVmed’s Strategic Advancements and Growth Potential Drive Buy Rating

Anthony Vendetti, an analyst from Maxim Group, reiterated the Buy rating on PAVmed (PAVM – Research Report). The associated price target remains the same with $4.00.

Anthony Vendetti has given his Buy rating due to a combination of factors that highlight PAVmed’s strategic advancements and potential for growth. PAVmed is actively commercializing its Veris Cancer Care Platform, which has shown promising developments, including the completion of a pilot program with the Ohio State University Comprehensive Cancer Center and the resumption of its implantable device development. These efforts are expected to enhance personalized cancer care and position the company for future success.
Moreover, PAVmed’s subsidiary, Lucid Diagnostics, is making significant strides with its EsoGuard testing, and a positive Medicare coverage determination is anticipated soon. This, coupled with the expansion of concierge medicine contracts and partnerships with major health systems, is expected to drive revenue growth. Financially, PAVmed is managing its resources effectively, with sufficient capital to support ongoing operations. The company’s diversification into the biopharma sector and its compelling valuation further reinforce the Buy rating, as these elements collectively indicate a strong potential for value appreciation.

Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, Nephros, and Lucid Diagnostics. According to TipRanks, Vendetti has an average return of -27.9% and a 22.06% success rate on recommended stocks.